Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Delayed Nasdaq 03:55:25 2023-09-29 pm EDT Intraday chart for Protagonist Therapeutics, Inc. 5-day change 1st Jan Change
16.68 USD -2.66% -2.54% +52.84%

Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating

May 18, 2022 at 06:53 am EDT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
JPMorgan Lowers Protagonist Therapeutics' Price Target to $34 From $36, Keeps Overweight Rating MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
JMP Securities Raises Protagonist Therapeutics' Price Target to $35 From $28, Keeps Market Outperform Rating MT
Protagonist Therapeutics Reports Positive Topline Results in Plaque Psoriasis MT
Protagonist Therapeutics Announces Positive Topline Results with Jnj-2113, the First and Only Oral Il-23 Receptor Antagonist Peptide in Development for Moderate-To-Severe Plaque Psoriasis CI
Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell 3000E Growth Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell Microcap Value Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000E Value Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000E Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell 3000 Growth Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell Microcap Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell 2500 Growth Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell Small Cap Comp Growth Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell 2000 Growth Index CI
Certain Common stock of Protagonist Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-JUN-2023. CI
Certain Warrants of Protagonist Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-JUN-2023. CI
Certain Performance Stock Units of Protagonist Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-JUN-2023. CI
Certain Restricted Stock Units of Protagonist Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-JUN-2023. CI
Certain Stock Options of Protagonist Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-JUN-2023. CI
Protagonist Therapeutics Says Oral Drug Candidate JNJ-2113 Showed Pharmacodynamics Activity in Humans in Recent Studies MT
Protagonist Reports Positive Results from Phase 1 and Pre-Clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sector Update: Health Care Stocks Steady Premarket Wednesday MT
Protagonist Therapeutics Prices $100 Million Common Stock Offering MT
Chart Protagonist Therapeutics, Inc.
More charts
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. Its clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company's Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned, investigational, orally delivered, gut-restricted alpha 4 beta 7 (?4?7) specific integrin antagonist for inflammatory bowel disease (IBD).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.13USD
Average target price
39.40USD
Spread / Average Target
+130.01%
Consensus
  1. Markets
  2. Equities
  3. Stock Protagonist Therapeutics, Inc. - Nasdaq
  4. News
  5. Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer